Lu-177 DGUL is a radiopharmaceutical agent specifically designed to target and treat prostate cancer cells by exploiting the overexpression of the prostate-specific membrane antigen (PSMA) on their surface. PSMA, a type II transmembrane glycoprotein, is predominantly found in prostate cancer cells, while its presence in normal tissues is relatively limited. This different ...View more